Molecular mechanisms of corticosteroid actions.

Glucocorticoids are the most effective therapeutic agents used for the treatment of chronic inflammatory diseases of the lung. They act by interacting with, and thereby activating, a specific cytoplasmic receptor (GR) which then migrates to the cell nucleus and inhibits inflammatory gene transcription. Inflammatory gene transcription is enhanced by activation of several intracellular signalling pathways which activate transcription factor such as NF-kappaB and AP-1. These transcription factors bind to DNA and induce local unwinding of the DNA structure allowing increased gene transcription. Glucocorticoids interfere with the ability of NF-kappaB and AP-1 to induce transcription by increasing the compaction of unwound chromosomal DNA in a process that involves deacetylation of histone proteins. A small number of asthmatic patients are resistant to the beneficial effects of glucocorticoids. This defect does not appear to be due to a reduced expression of GR but may be associated with a failure of GR to translocate into the nucleus and/or a reduced ability to inhibit AP-1 actions.

[1]  I. Adcock,et al.  Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1β-Induced Histone H4 Acetylation on Lysines 8 and 12 , 2000, Molecular and Cellular Biology.

[2]  A. Sousa,et al.  In vivo resistance to corticosteroids in bronchial asthma is associated with enhanced phosyphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation. , 1999, The Journal of allergy and clinical immunology.

[3]  S. Larsson,et al.  IL‐2 and IL‐4 counteract budesonide inhibition of GM‐CSF and IL‐10, but not of IL‐8, IL‐12 or TNF‐α production by human mononuclear blood cells , 1999, British journal of pharmacology.

[4]  E. Gelfand,et al.  Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. , 1999, The Journal of allergy and clinical immunology.

[5]  I. Adcock,et al.  Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes. , 1998, The Journal of clinical investigation.

[6]  J. Bousquet,et al.  Glucocorticoid receptors in bronchial epithelial cells in asthma. , 1998, American journal of respiratory and critical care medicine.

[7]  S. Szefler,et al.  Fluticasone propionate results in improved glucocorticoid receptor binding affinity and reduced oral glucocorticoid requirements in severe asthma. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[8]  I. Adcock,et al.  Transcription factors and asthma. , 1998, The European respiratory journal.

[9]  A. Wolffe,et al.  Transcription: Gene control by targeted histone acetylation , 1998, Current Biology.

[10]  P. Barnes,et al.  Anti-inflammatory actions of glucocorticoids: molecular mechanisms. , 1998, Clinical science.

[11]  A. Muñoz,et al.  Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. , 1997, Genes & development.

[12]  S. Wenzel,et al.  Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. , 1997, American journal of respiratory and critical care medicine.

[13]  I. Adcock,et al.  Glucocorticoid receptor localization in normal and asthmatic lung. , 1996, American journal of respiratory and critical care medicine.

[14]  A. Manning Transcription factors: a new frontier for drug discovery , 1996 .

[15]  M. Beato,et al.  Control of Transcription by Steroid Hormones a , 1996, Annals of the New York Academy of Sciences.

[16]  T. Lee,et al.  Hypothalamic-pituitary-adrenal axis in corticosteroid-resistant bronchial asthma. , 1996, American journal of respiratory and critical care medicine.

[17]  I. Adcock,et al.  Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma , 1995, The Journal of experimental medicine.

[18]  I. Adcock,et al.  Steroid resistance in asthma. , 1995, QJM : monthly journal of the Association of Physicians.

[19]  P. Barnes,et al.  Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. , 1995, The Journal of clinical investigation.

[20]  I. Adcock,et al.  Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma. , 1995, Journal of immunology.

[21]  P. Barnes,et al.  Inhaled glucocorticoids for asthma. , 1995, The New England journal of medicine.

[22]  R. Brattsand,et al.  Effects of a corticosteroid, budesonide, on alveolar macrophage and blood monocyte secretion of cytokines: differential sensitivity of GM-CSF, IL-1 beta, and IL-6. , 1994, Pulmonary pharmacology.

[23]  S. Szefler,et al.  Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. , 1993, Journal of immunology.

[24]  G. Cirino,et al.  Human recombinant lipocortin 1 (annexin 1) has anticoagulant activity on human plasma in vitro. , 1993, Journal of lipid mediators.